<DOC>
	<DOCNO>NCT02446223</DOCNO>
	<brief_summary>Evaluate Efficacy Safety Large-Scale Field-Directed Topical Therapy Actinic Keratosis Chest w/Ingenol Mebutate 0.015 %</brief_summary>
	<brief_title>Evaluate Efficacy Safety Large-Scale Field-Directed Topical Therapy Actinic Keratosis Chest w/Ingenol Mebutate 0.015 %</brief_title>
	<detailed_description>This open-label study evaluate efficacy safety ingenol mebutate gel , 0.015 % use topical therapy actinic keratosis chest . Subjects present 4 actinic keratosis one continuous 100cm2 area chest meet inclusion/exclusion criterion enrol study . Treatment investigational product ( IP ) apply three continuous day . The investigator guide application IP in-office Day 0 subject instruct self-administer IP Days 1 2 . Follow-up visit schedule Days 1 , 3 , 10 , 17 , 24 59 . Prior treatment visit , investigator ass subject 's treatment area lesion count follow visit 4 , 5 , 6 7 evaluation clearance . Pre-treatment photography also collect baseline follow visit .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . Male female least 18 year age . 2 . Subjects willing comply study requirement . 3 . The presence four clinically typical actinic keratosis within one contiguous area chest 100cm2 . 4 . For female subject childbearing potential willing use acceptable form birth control entire course study . All systemic birth control measure must consistent use least 30 day prior entry study . A female consider NOT childbearing potential postmenopausal least one ( 1 ) year , without uterus , without ovary bilateral tubal ligation . Acceptable method birth control : oral contraceptive , contraceptive patches/rings/implants Norplant , DepoProvera , doublebarrier method ( e.g . condom spermicide ) abstinence . 5 . Subjects willing refrain use topical product contain alphahydroxy acid , retinoic acid , retinol , salicylic acid , vitamin C/D ( derivative ) treatment area 7 Days prior entire study period 1 . Known hypersensitivity , prior allergic reaction , prior chest treatment ingenol mebutate gel . 2 . Treatment area contain hypertrophic hyperkeratotic lesion , cutaneous horn lesion previously respond standard treatment . 3 . Presence skin condition disease might interfere diagnosis evaluation study parameter ( i.e. , atopic dermatitis , eczema , psoriasis , seborrheic dermatitis ) . 4 . Subjects receive ablative laser treatment chest must discontinue treatment least 6 month prior enter study . 5 . Subjects receive Intense Pulse Light treatment chest must discontinue treatment least 30 day prior enter study . 6 . Within 3 month study entry treatment may interfere evaluation treatment area ( e.g . topical therapy actinic keratosis chest , topical corticosteroid , topical retinoids , ultraviolet B phototherapy , immunosuppressive , immunomodulating , cytotoxic medication ) expect use abovementioned therapy treatment area list duration study . 7 . Within 3 month study entry topical treatment treatment area actinic keratosis include , limited imiquimond , 5 fluorouracil , diclofenac liquid nitrogen . 8 . Within 6 month study entry treatment PolyLlactic acid ( PLLA ; Sculptra Aesthetic ) may interfere evaluation treatment area . 9 . Within 7 day study entry use selftanners , excessive exposure sunlight artificial UV light ( e.g . : use tan beds/booths and/or sunbathe ) expectation list time study within treatment area . 10 . Any systemic disease yet stabilize least six ( 6 ) Months prior enter study . 11 . A significant history current evidence medical , psychological disorder , investigator 's opinion , would interfere objective study 12 . Pregnant nursing woman woman plan pregnancy study period . 13 . Any unhealed skin lesion wound within treatment area . 14 . Existence one ( 1 ) suspect basal cell carcinoma squamous cell carcinoma within treatment area . 15 . Current participation participation within 30 day prior start study drug investigational device research study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Actinic Keratosis AKs Chest Pre-Cancer</keyword>
</DOC>